Adia Nutrition, Inc. Overview
Pro stress-test →Adia Nutrition offers medical treatments and nutritional supplements through three segments: Biolete, Adia Med, and Adia Labs. The company provides autologous hematopoietic stem cell transplantation (AHSCT) treatments for multiple sclerosis patients and operates Adia Med clinics to perform stem cell treatments, while Adia Labs procures and sells stem cell products. In Q1 2026, the company reported 146% year-over-year revenue growth to $176,275, driven by medical procedures and new biologics sales.
Strategic Profile
Pro stress-test →The company, undergoing a corporate name change to Adia Med, Inc., has significantly shifted its business model toward advanced medical treatments and biologics. The company has secured Institutional Review Board approval for four clinical studies using AdiaVita stem cell and exosome therapies, including a flagship kidney health study for chronic kidney disease and an autism study in Winter Park that has completed enrollment.
Competitive Landscape
Pro stress-test →Adia Nutrition competes in the regenerative medicine and stem cell therapy space, where it operates clinics offering PRP, AHSCT, orthopedic care, pain management, and wound repair, while also developing biologic products including AdiaVita and AdiaLink. Primary competitors include established regenerative medicine providers and stem cell therapy clinics, though the company's clinical validation pathway for insurance reimbursement represents a differentiation strategy in a fragmented market.
Industry Context
Adia Nutrition, Inc. operates in Stem cell and regenerative medicine therapies.
Key facts
Founded: 2004 (as PivX Solutions; renamed Adia Nutrition in May 2004) · Headquarters: Winter Park, Florida, US · Employees: Not disclosed · Revenue: $700,508 (2025); $176,275 (Q1 2026) · Market cap: Not available (OTC micro-cap)